FOR IMMEDIATE RELEASE

AMP and CAP Formalize Collaboration to Advance Molecular and General Pathology

AMP and CAP also Team with ASCO to Launch New Physician Education Tumor Board Series

Bethesda, MD and Washington, DC, February 12, 2015: The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular laboratory professionals, together with the College of American Pathologists (CAP) announced today the signing of memorandum of understanding to foster synergies between the sub-specialty of molecular pathology and the general practice of pathology. The agreement will cultivate and expand activities already established between the two groups and will also allow for future exploration of other mutually beneficial areas including advocacy, genomics education, and the development of practice guideline initiatives, both evidenced-based and consensus-based.

“Genomic information is increasingly important to patient care, and the CAP and AMP already have made tremendous progress advancing the accuracy and availability of genomic-related laboratory tests,” said CAP President Gene N. Herbek, MD, FCAP, and medical director at the Nebraska Methodist Health System in Omaha, Neb. “Formalizing the CAP and AMP relationship signals a shared commitment to ensure that physicians and their patients have the resources they need to benefit from advanced testing and targeted treatments.”

AMP and the CAP have also teamed with the American Society of Clinical Oncology (ASCO) to launch the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Each month the Molecular Oncology Tumor Boards will feature a case-based discussion involving genetic or genomics in the treatment of cancer. Two rotating faculty members, a medical oncologist and a pathologist, will lead the case discussion each month, provide input, and later post a summary of the case discussion that addresses actionable aberrations identified and treatment options available based on clinical parameters.

“We hope that the newly formed alliance with the CAP and our collaboration with ASCO will bring our respective fields of expertise closer together and increase the level of knowledge-sharing of new testing methodologies,” said AMP President, Janina Longtine, MD. “Given the rapid evolution of the genomics field, it’s critically important that we look for opportunities to connect expert organizations that can greatly impact awareness, education, and understanding of information that can improve medical practice and patient care.”

AMP’s Training and Educational Committee Chair, Laura Tafe, MD, FCAP, of Dartmouth-Hitchcock Medical Center, Lebanon, N.H., will help develop content for the Molecular Oncology Tumor Board series. Dr. Tafe believes that the new educational platform allows and encourages a multidisciplinary discussion of this rapidly growing area of cancer care and noted, “These discussions are creating a new way to directly connect expert pathologists with medical oncologists and provide a forum to discuss and educate on actionable treatment options.” Dr. Tafe will participate in the Molecular Oncology Tumor Board series in February, co-presenting a
case study in lung cancer. Access to the Molecular Oncology Tumor Boards is available for free through the ASCO Connection website, www.ASCOConnection.org.

About the College of American Pathologists
As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP’s Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,600 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at CAP.ORG. Follow CAP on Twitter at @PATHOLOGISTS.

About the American Society of Clinical Oncology
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.cancer.net.

About the Association for Molecular Pathology
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration on the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. More information about AMP is available at www.amp.org.

MEDIA CONTACTS:
Maurissa Messier on behalf of AMP
Maurissa@bioscribe.com
760-659-6700

Kerry Lydon
College of American Pathologists
800-323-4040, ext. 7844
media@cap.org